✕
Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
 简体中文
(Simplified Chinese) 繁體中文
(Traditional Chinese)
Life, illuminated.
Advancing fluorescent technology to help improve patient care.

MediBeacon is a medical technology company specializing in the advances of fluorescent tracer agents and transdermal measurement. The science is complex, but the outcomes are simple to understand. How it works >>

PRECLINICAL
MediBeacon technology is available for preclinical use.
CLINICAL
MediBeacon technologies are progressing through clinical trials.*
There are no limits to our thinking or what that thinking can accomplish.
Focus areas for
fluorescent agent-
based systems include:
Nephrology

Point of care measurement of renal function **
-Learn More

Gastroenterology

Point of care gastrointestinal
permeability measurement
-Learn More

Ophthalmology

Fluorescent agent angiography
-Learn More

Surgery

Fluorescent tracer agent
use in surgery
-Learn More

Publications
MediBeacon Publications
Preclinical Publications
Industry Literature
Acute Kidney Injury complicates as many as
36%of cardiac operations worldwide
  • Doubling total hospital costs
  • AKI predicts increased long-term mortality
  • Clinicians have limited tools to identify patients at risk of AKI
  • Identification of high-risk patients preoperatively could affect clinical decision making
- The Society of Thoracic Surgeons, Mitchell Rosner, John Kellum, and Claudio Ronco et al., Preoperative renal functional reserve predicts risk of Acute Kidney Injury (AKI) after cardiac operation, 2018

MediBeacon’s Transdermal Glomerular Filtration Rate Measurement System (TGFR) has the potential to provide important information to cardiologists to address this challenge.
THE UNMET MEDICAL NEED IN THE INTENSIVE CARE UNIT:
Acute Kidney Injury occurred in more than
50%
of ICU patients.
- Intensive Care Medicine, Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study, 2015
MediBeacon’s Transdermal Glomerular Filtration Rate Measurement System (TGFR) has the potential to provide important information to Intensive Care Unit professionals to address this challenge.

United States
MediBeacon Inc.
425 N. New Ballas Road
Suite 100
St. Louis, MO 63141
P: (314) 269-5808

Germany
MediBeacon GmbH
Cubex41
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
P: +49 (0)621-150283-15

Greater China
(Exclusive Commercial Partner)
Huadong Medicine Co., Ltd
Telephone: 4008-269-985
+86-(0)571-89908581
Zip: 310011
Address: No.866. Moganshan Road, Hangzhou, Zhejiang Province, China
Email: info@eastchinapharm.com

Science How it Works R&D Platform Product Pipeline Patent Estate Preclinical Clinical Focus Areas Nephrology Gastroenterology Ophthalmology Surgery In Discovery
Publications MediBeacon Publications Preclinical Publications Industry Literature Company History People By the Numbers Quality Commitment News/Media Contact Get Updates Investors General Questions

*MediBeacon products are in various stages of clinical development and are not yet approved for human use.

**The Transdermal GFR Measurement System (TGFR) is intended to measure Glomerular Filtration Rate (GFR) in patients with impaired or normal renal function. References on this website to measured kidney function and measured renal function refer to the measured GFR.

Terms and Conditions | Privacy Policy | © 2021 MediBeacon All Rights Reserved.

COOKIE CONSENT: We use cookies and similar technologies to recognize your repeat visits and preferences, as well as to analyze traffic, among other things. To learn more about cookies, view our Privacy Policy. By clicking “I Accept” on this banner, or using our site, you consent to the use of cookies unless you have disabled them.